L. Brandefors

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

D. Swinkels, A. Stamatoullas, C. Craddock, 2020, Leukemia.

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

R. Greil, M. Ziepert, W. Stevens, 2012 .

Familial Waldenstrom’s macroglobulinemia and relation to immune defects, autoimmune diseases, and haematological malignancies – A population-based study from northern Sweden

E. Kimby, J. Lindh, B. Melin, 2016, Acta oncologica.

Prognostic factors and primary treatment for Waldenström macroglobulinemia – a Swedish Lymphoma Registry study

E. Kimby, J. Lindh, B. Melin, 2018, British journal of haematology.

Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia

E. Kimby, C. Buske, J. Dreyhaupt, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First – Line Treatment of Waldenstrom’s Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial

E. Kimby, M. Dimopoulos, C. Buske, 2020 .

Clinical characteristic and outcome of lymphoplasmacytic lymphoma of non‐Waldenstrom macroglobulinemia type: A Swedish lymphoma registry study

B. Sander, E. Kimby, K. Lundqvist, 2021, British journal of haematology.

Incidence and inheritance of hyperphosphorylated paratarg-7 in patients with Waldenstrom’s macroglobulinaemia in Sweden

E. Kimby, M. Pfreundschuh, J. Lindh, 2019, Acta oncologica.

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial

L. Möllgård, L. Saft, H. Garelius, 2014, Blood Cancer Journal.

Nationwide Assessment of Patient Trajectories in Mantle Cell Lymphoma: The Swedish MCLcomplete Project

M. Jerkeman, I. Glimelius, K. E. Smedby, 2023, HemaSphere.